Historical Stock Chart
1 Month : From Nov 2019 to Dec 2019
By Colin Kellaher
Merck & Co. (MRK) on Monday said vericiguat, an investigational drug it is developing with Bayer AG (BAYN.XE), met the primary efficacy endpoint in a phase 3 study in patients with worsening chronic heart failure.
The Kenilworth, N.J., drug maker said vericiguat reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction compared to placebo when given in combination with available heart failure therapies.
Merck and Germany's Bayer formed a worldwide collaboration in October 2014 in the field of soluble guanylate cyclase modulators such as vericiguat.
Merck said the companies will present the study results at an upcoming medical meeting in 2020.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
November 18, 2019 06:59 ET (11:59 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.